Navigation Links
ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results

TUCSON, Ariz., May 15 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX), a biopharmaceutical company developing and commercializing therapies for vascular disorders, today reported financial results for the first quarter ended March 31, 2008 and discussed recent corporate highlights.

Corporate Highlights:

-- Entered into agreement with Abbott Laboratories satisfying remaining

debt obligation under non-recourse promissory note issued in connection

with the Company's urokinase acquisition.

-- Signed letter of intent to sell urokinase inventory and related assets

to Microbix Biosystems for $17 million in cash: $12 million at closing

and $5 million upon achievement of an inventory stability milestone.

-- Identified strategic funding to continue advancement of its core

SonoLysis program upon closing of urokinase divestiture with Microbix


Bradford A. Zakes, President and CEO of ImaRx stated, "Through the satisfaction of our debt obligation with Abbott under favorable terms and the pending divestiture of our urokinase asset to Microbix, we will have successfully gained access to operating capital that is non-dilutive to our shareholders. Taken together, these events have provided us the strategic alternative to continue the advancement of our core SonoLysis technology within ImaRx."

Financial Results

Revenue for the first quarter ended March 31, 2008 rose to $1.9 million from $1.2 million for the first quarter ended March 31, 2007. Increased sales of urokinase, which ImaRx began commercializing in October 2006, drove the revenue increase for the quarter.

Net loss for the first quarter of 2008 was $2.5 m

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ImaRx Postpones Release of First Quarter 2008 Financial Results
2. ImaRx Schedules Release of First Quarter 2008 Financial Results
3. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
4. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
5. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
6. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
7. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
8. ImaRx to Report Corporate Updates and 4Q07 Financial Results
9. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
10. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Nile Therapeutics Reports 2008 First Quarter Financial Results
Post Your Comments:
(Date:8/20/2014)... RALEIGH, N.C. , Aug. 20, 2014 /PRNewswire/ ... clinical research services located in Raleigh, ... Bradford Evans as Vice President of ... Administration, Brad will oversee all corporate processes, including ... to joining Clintrax Global, Brad worked as an ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
(Date:8/20/2014)... -- Decision Resources Group finds that the vascular access device market in ... India and China (BRIC) ... the size of the United States market ... faster growth as a result of strong economic expansion, improving access ... from Decision Resources Group,s coverage of the BRIC vascular access device ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Clintrax Global, Inc. Announces Addition to Executive Team 2Seeing a molecule breathe 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... N.J., Sept. 12 Schering-Plough,Corporation (NYSE: SGP ) ... aggregate principal amount of 6.00% Senior Notes due 2017 ... due 2037 through,an underwritten registered public offering. The offering ... customary closing conditions. The global coordinator for the ...
... Inc.,(Nasdaq: MEDX ) announced today that it is ... Growth Conference in New York City on Tuesday,September 18, ... be,webcast live and will be available for replay through ... Medarex website via the Internet at, . ...
... SAN DIEGO, Sept. 12 Gen-Probe Incorporated,(Nasdaq: GPRO ... Bank of,America,s 37th Annual Investment Conference in San Francisco ... (5:30 p.m. Eastern Time).,The presentation is scheduled to be ... the investor information section of Gen-Probe,s website,at ...
Cached Biology Technology:Schering-Plough Announces Pricing of Senior Notes Offering 2Schering-Plough Announces Pricing of Senior Notes Offering 3Gen-Probe to Webcast Presentation at Bank of America's 37th Annual Investment Conference 2
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... the journal Carcinogenesis by researchers at the ... protein adenomatous polyposis coli (APC) in suppressing colorectal cancer ... U.S. , Lead author Kristi Neufeld, associate professor in ... Cancer Biology program at the KU Cancer Center, has ... understand the various activities of APC, a protein whose ...
(Date:8/21/2014)... designed by an international standards process, will be available ... an invited review published in the OnlineFirst version of ... the official journal of the American Society for Parenteral ... reduce the occurrence of misconnection that can be harmful ... are used to join medical devices, components, and accessories ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3New feeding tube connectors will improve patient safety 2
... at Universitat Autnoma de Barcelona (INc-UAB) identified the fundamental ... associated with synaptic activity. The discovery, published in the ... study a new target that could help to understand ... known to cause early cognitive deficit, and the neurodegeneration ...
... NC In a paper published today in the journal ... North Carolina at Chapel Hill demonstrates a simple, cost-effective technique ... the structures, and ultimately the functions, of the RNA molecules ... When cell behavior goes wrong, diseases including cancer and ...
... gene sequencing technology, researchers have demonstrated that the gene ... Leukemia, AML, one of the most common types of ... allows for the rapid and comprehensive detection of gene ... online April 15 in Nature , are a ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 23-D RNA modeling opens scientific doors 2Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
... U. Desselberger (1995) • This book ... together classical and molecular techniques currently ... infections and analysis of virus-specific antibodies ... are presented covering immunoassays, blotting and ...
... Kits provide rapid and efficient removal of ... and salts from PCR products (Figure 1). ... two Binding Buffer options for fragments >100 ... performed in either single column or 96-well ...
... Blunt TOPO PCR Cloning Kit offers ... high-efficiency (>=95%) cloning of blunt-end PCR ... The kit includes the linearized and ... 5-minute bench-top ligations without ligase (1). ...
Biology Products: